Serum EBI-3 Protein Levels in Behçet's Disease

September 22, 2026 updated by: Shrouk Samir Mohamed, Assiut University

Serum Epstein-Barr Virus-induced Gene 3 Protein Levels in Patients With Behçet's Disease

This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Behçet's disease is a chronic multisystem inflammatory disorder. Serum EBI-3 protein levels may reflect inflammatory activity.

This observational study will include adult patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease and age-matched healthy controls. Serum EBI-3 protein levels will be measured by ELISA.

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients with Behçet's disease attending the Physical Medicine, Rheumatology and Rehabilitation Department at Assiut University Hospitals, and healthy controls.

Description

Inclusion Criteria:

  • - Age 18 years or older
  • Diagnosis of Behçet's disease according to the International Criteria for Behçet's Disease (cases)
  • Healthy individuals without autoimmune or inflammatory diseases (controls)
  • Written informed consent

Exclusion Criteria:

  • - Other autoimmune disorders (RA, SLE, psoriatic arthritis, ankylosing spondylitis)
  • Acute or chronic infection
  • Malignancy or history of malignancy
  • Chronic liver disease or advanced chronic kidney disease
  • Pregnancy or lactation
  • Vasculitis caused by diseases other than Behçet's disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
Behçet's Disease

Patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease.
Healthy Controls

Age-matched healthy individuals without autoimmune or inflammatory diseases.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean serum EBI-3 protein level
Time Frame: Baseline

Mean serum Epstein-Barr virus-induced gene 3 (EBI-3) protein concentration measured by ELISA in patients with Behçet's disease compared with healthy controls.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum EBI-3 level according to disease activity
Time Frame: Baseline

Mean serum EBI-3 protein concentration according to Behçet's Disease Current Activity Form (BDCAF) score.
Baseline
Serum EBI-3 level in patients with vascular involvement
Time Frame: Baseline

Mean serum EBI-3 protein concentration in patients with and without vascular involvement
Baseline
Serum EBI-3 level in patients with ocular involvement
Time Frame: Baseline

Mean serum EBI-3 protein concentration in patients with and without ocular involvement.
Baseline
Serum EBI-3 level in patients with neurological involvement
Time Frame: Baseline

Mean serum EBI-3 protein concentration in patients with and without neurological involvement.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Chair: Gehan I Abdelraziq, prof, Physical Medicine, Rheumatology and Rehabilitation Department, Assiut University Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 26, 2026

Primary Completion (Estimated)

September 26, 2027

Study Completion (Estimated)

January 25, 2028

Study Registration Dates

First Submitted

September 22, 2026

First Submitted That Met QC Criteria

September 22, 2026

First Posted (Actual)

September 28, 2026

Study Record Updates

Last Update Posted (Actual)

September 28, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EBI3-Behcet-Assiut-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe